论文部分内容阅读
目的探讨促肠动力药物莫沙必利治疗慢性便秘患者的临床疗效。方法选取2015年1月至2016年1月于广东省英德市人民医院就诊的50例慢性便秘患者作为研究对象,随机将其分为观察组与对照组,各25例。对照组患者给予常规治疗,观察组患者在对照组治疗基础上采用促肠道动力类药物莫沙必利进行治疗,比较两组患者临床效果、干预前后大便情况及其他伴随症状情况。结果观察组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);干预后,观察组患者大便症状积分、伴随症状积分均明显低于对照组,差异均有统计学意义(均P<0.05)。结论促肠动力药物莫沙必利治疗慢性便秘临床疗效显著。
Objective To investigate the clinical efficacy of promoting intestinal motility drug mosapride in patients with chronic constipation. Methods Fifty patients with chronic constipation who were treated in Yingde People’s Hospital of Guangdong Province from January 2015 to January 2016 were selected as subjects and randomly divided into observation group and control group with 25 cases each. Patients in the control group were treated with mosapride, a prokinetic drug, on the basis of the control group. The clinical effects, stool situation before and after the intervention, and other accompanying symptoms were compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant (P <0.05); after intervention, the stool symptom score and attendant symptom score in observation group were significantly lower than those in control group Significance (both P <0.05). Conclusion Conclu-sive drug mosapride in the treatment of chronic constipation has a significant clinical effect.